Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Alnylam Pharmaceuticals, Inc. (NQ: ALNY)
30.25 USD  +0.26 (+0.87%)
Streaming Delayed Price  /  Updated: 4:00 PM EDT, Jun 19, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Alnylam Pharmaceuticals, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Alnylam to Webcast Presentation at Goldman Sachs 34th Annual Global Healthcare Conference
June 06, 2013
from Business Wire News Releases
Alnylam to Webcast Presentation at Deutsche Bank 38th Annual dbAccess Health Care Conference
May 21, 2013
from Business Wire News Releases
Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate Synthase-1 (ALAS-1) for the Treatment of Porphyria
May 17, 2013
from Business Wire News Releases
Alnylam to Webcast Presentation at 2013 UBS Global Healthcare Conference
May 15, 2013
from Business Wire News Releases
Alnylam to Webcast Presentation at 2013 Bank of America Merrill Lynch Health Care Conference
May 08, 2013
from Business Wire News Releases
Alnylam Pharmaceuticals Reports First Quarter 2013 Financial Results
May 06, 2013
from Business Wire News Releases
Alnylam to Webcast Conference Call Discussing First Quarter 2013 Financial Results
April 29, 2013
from Business Wire News Releases
Alnylam to Webcast Presentation at 12th Annual Needham Healthcare Conference
April 23, 2013
from Business Wire News Releases
Alnylam Initiates Phase I Clinical Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)
March 18, 2013
from Business Wire News Releases
FDA Programs Designed to Speed Up Approval Process Helps Send Drug Approvals to a 15-Year High in 2012
March 11, 2013
Five Star Equities Provides Stock Research on Aegerion Pharmaceuticals and Alnylam Read More
from Marketwired News Releases
Alnylam to Webcast Presentation at Barclays Global Healthcare Conference
March 05, 2013
from Business Wire News Releases
Alnylam to Webcast Presentation at Cowen and Company 33rd Annual Health Care Conference
February 26, 2013
from Business Wire News Releases
Free Research Report on Alcatel-Lucent, Alnylam Pharmaceuticals, Inc., Hunt (J.B.) Transport Services, Inc., Westlake Chemical Corp. and Equity One, Inc.
February 14, 2013
from Marketwired News Releases
Corporate Leaders Receive Thirteenth Annual Emerald Asset Management “E-3 Awards”
February 11, 2013
from Business Wire News Releases
Biotechnology Industry Soars in 2012 as FDA Drug Approvals at a 15-Year High
February 11, 2013
Research Driven Investing Provides Stocks Research on Alnylam and Arena Read More
from Marketwired News Releases
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
February 07, 2013
from Business Wire News Releases
Alnylam to Webcast Presentation at Upcoming Investor Conferences
February 05, 2013
from Business Wire News Releases
Over 25 Companies to Present at Emerald Groundhog Day Investment Forum
February 05, 2013
from Business Wire News Releases
Karyopharm Therapeutics Announces Ken Weg & Barry Greene Join Board of Directors; Dr. Sharon Shacham Named President of Research & Development
February 05, 2013
from GlobeNewswire News Releases
The Medicines Company and Alnylam Form Strategic Alliance to Develop and Commercialize RNAi Therapeutics Targeting PCSK9 for the Treatment of Hypercholesterolemia
February 04, 2013
from Business Wire News Releases
Tekmira's LNP Technology Highlighted in Peer-Reviewed Publication, Cancer Discovery
January 31, 2013
Results Outline Most Comprehensive Human Experience to Date for RNAi Therapeutics Delivered With Lipid Nanoparticles (LNPs) Read More
from GlobeNewswire News Releases
Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2012 Financial Results
January 31, 2013
from Business Wire News Releases
Empire Asset Management Company Initiates Coverage
January 31, 2013
from PR Newswire
Alnylam and Collaborators Publish Results from Phase I Clinical Trial and Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer
January 30, 2013
from Business Wire News Releases
Free Research Reports on ALNY, CYTR, IQNT and UNIS Issued by the Bedford Report
January 17, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit Read More
from Marketwired News Releases
Alnylam Pharmaceuticals Announces Exercise of Over-Allotment Option in Public Offering of Common Stock
January 16, 2013
from Business Wire News Releases
Alnylam Pharmaceuticals Prices Public Offering of Common Stock
January 15, 2013
from Business Wire News Releases
Alnylam Pharmaceuticals Announces Proposed Public Offering of $125 Million of Common Stock
January 14, 2013
from Business Wire News Releases
The Reason It Trades, What's Moving DNDN, ISIS and ALNY
January 14, 2013
from Marketwired News Releases
Alnylam Provides Key 2013 – 2014 Goals for RNAi Therapeutics Pipeline
January 06, 2013
from Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here